Clinical Trials Browser

spartalizumab × Other solid neoplasm × Clear all

NCT05155332 2026-05-20

A Study to Test Different Doses of BI 1831169 Alone and in Combination With an Anti-PD-1 Antibody in People With Different Types of Advanced Cancer (Solid Tumors)

Phase 1 Suspended

Other solid neoplasm

Solid Tumors

NCT06470971 2026-01-20

Siltuximab for the Prevention of Severe Immune-Related Adverse Events During Immune Checkpoint Inhibitor Rechallenge in Patients With Advanced Cancer, CIRES Trial

Phase 2 Recruiting

Other solid neoplasm

Advanced Malignant Solid Neoplasm

NCT05210413 2026-01-15

SPARTO

Phase 1/2 Active not recruiting

Other solid neoplasm

Refractory or Recurrent Solid Tumor

NCT06265727 2026-01-08

A Phase 1/2 Study to Investigate CRB-701 in Solid Tumors

Phase 1/2 Recruiting

Other solid neoplasm

Solid Tumor, Adult

NCT07245901 2025-11-24

Safety and Tolerability of a mRNA Vaccine Encoding Tumor-Specific Circular RNA Antigens in Combination With Anti-PD-1 Monoclonal Antibody in Patients With Advanced Solid Tumors

Phase 1/2 Not yet recruiting

Other solid neoplasm

Solid Tumor

NCT04058756 2025-10-07

Rollover Study for Continued Safety and Tolerability in Subjects Treated With Spartalizumab Alone or in Combination With Other Study Treatments

Phase 1 Active not recruiting

Other solid neoplasm

Advanced Solid Tumors

NCT03034304 2025-07-24

A Phase I Clinical Study for Evaluating the Safety and Efficacy of MASCT-I in Patients With Advanced Solid Tumors

Phase 1 Terminated

Other solid neoplasm

Advanced Solid Tumors

NCT05978102 2025-07-23

A Dose Escalation and Dose Expansion Clinical Study of STI-7349 in Subjects With Advanced Solid Tumors

Phase 1/2 Recruiting

Other solid neoplasm

Advanced Solid Tumor

NCT06603844 2025-06-03

First-in-human Study of CRB-601-01 to Treat Patients With Advanced Solid Tumor.

Phase 1/2 Recruiting

Other solid neoplasm

Solid Tumor

NCT04237649 2025-05-18

KAZ954 Alone and With PDR001, NZV930 and NIR178 in Advanced Solid Tumors

Phase EARLY_PHASE1 Terminated

Other solid neoplasm

Solid Tumors

NCT04802876 2025-03-21

ACROPOLI

Phase 2 Active not recruiting

BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckOther solid neoplasmSarcomaThoracic

Adenocarcinoma Of Esophagus, Adenocarcinoma of Lung, Squamous Cell Carcinoma of Head and Neck, Carcinoma, Ovarian Epithelial, Uveal Melanoma, Anus Neoplasms, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Carcinoma, Hepatocellular, Melanoma, Mesothelioma, Neoplasms, Unknown Primary, Sarcoma, Thyroid Neoplasms, Cholangiocarcinoma, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT04672434 2024-12-09

Sym024 Monotherapy and in Combination With Sym021 in Patients With Advanced Solid Tumor Malignancies

Phase 1 Completed

GastrointestinalGynecologicHead & NeckOther solid neoplasmThoracic

Squamous Cell Carcinoma of Head and Neck, Uterine Cervical Neoplasms, Esophageal Neoplasms, Mesothelioma, Neoplasm Metastasis, Stomach Neoplasms, Colorectal Neoplasms, Cholangiocarcinoma

NCT05522582 2024-10-26

Methotrexate Combined With Immunotherapy During Radiotherapy for Solid Tumors

Phase 2 Active not recruiting

Other solid neoplasm

Solid Tumors

NCT03523819 2024-09-19

A Study of CS1002 in Subjects with Advanced Solid Tumors

Phase 1 Completed

Other solid neoplasm

Solid Tumor, Adult

NCT03874897 2024-04-30

Chimeric Antigen Receptor T Cells Targeting claudin18.2 in Solid Tumors.

Phase 1 Completed

Other solid neoplasm

Advanced Solid Tumor

NCT04301557 2024-04-23

PD1 Antibody Toripalimab and Chemoradiotherapy for dMMR/MSI-H Locally Advanced Colorectal Cancer

Phase 2 Unknown

GastrointestinalOther solid neoplasm

DMMR Colorectal Cancer

NCT03393858 2024-02-07

Combination of Immunotherapy and Hyperthermia in Advanced Malignant Mesothelioma

Phase 1/2 Terminated

Other solid neoplasmThoracic

Mesothelioma, Malignant, Neoplasms

NCT05699811 2023-04-28

IFNα Expressing Mesenchymal Stromal Cells for Locally Advanced/Metastatic Solid Tumors

Phase 1/2 Recruiting

Other solid neoplasm

Locally Advanced or Metastatic Solid Tumors

NCT05204862 2023-04-03

Phase 1/2 Study of TU2218 Alone and in Combination With Checkpoint Inhibitors in Patients With Advanced Solid Tumors

Phase 1/2 Recruiting

Other solid neoplasm

Advanced Solid Tumor

NCT02460224 2022-02-10

Safety and Efficacy of LAG525 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies.

Phase 1/2 Completed

490 enrolled 77 charts

DermatologicGenitourinaryOther solid neoplasmThoracic

Carcinoma, Non-Small-Cell Lung, Kidney Neoplasms, Melanoma, Mesothelioma

NCT03704246 2021-03-04

Recombinant Human Anti-PD-1 Monoclonal Antibody HX008 Injection for the Treatment of Advanced Solid Tumors

Phase 2 Unknown

Other solid neoplasm

Advanced Solid Tumor

NCT04478461 2020-11-13

Safety, Tolerability, and Pharmacokinetics of MW11 in Patients With Advanced Solid Tumors

Phase 1 Unknown

Other solid neoplasm

Advanced Solid Tumor

NCT04569916 2020-09-30

Radiotherapy Combined With Irinotecan and Apatinib Followed by PD-1 Antibody and Apatinib for Advanced Solid Tumors

Phase 2 Unknown

Other solid neoplasm

Solid Tumor

NCT03975036 2019-06-05

Clinical Study on the Second-line and Above Treatment of Advanced Solid Tumor With Anlotinib Combined With Pd-1 Antibody

Phase 2/3 Unknown

Other solid neoplasm

Advanced Solid Tumor